Plain-English translation of NCT07375966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that dissolves blood clots in the brain during stroke. Some people receive a standard first dose, but if they don't show improvement after one hour, researchers want to know if a second dose might help. The study will compare patients who receive the second dose with those who don't to see which approach works better.
Many stroke patients who receive standard clot-busting treatment still don't recover well because the blood clot doesn't fully dissolve, especially when the clot is large. This medication is easier to give than current treatments and may work better, so researchers want to test whether a second dose could save more patients from permanent disability.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have already received your first dose of medication in the emergency room within 4.5 hours of your stroke. One hour later, if you haven't improved enough, you'll be randomly assigned to either receive a second dose of the medication or receive standard care without it. You'll have imaging scans to confirm the clot is still there, and doctors will closely monitor your neurological improvement over the following hours and days to see how well the treatment works.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
China